



نتقدم بثقة
Moving Forward
with Confidence



To:

Pharmacist Incharge, Armed Forces Hospital (AT Khoudh & Salalah)
Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahda Hospital
Director of Pharmaceutical Care, DGHS, Muscat Governorate
Director of Pharmaceutical Care, DGHS, Al Dakhliya Governorate
Director of Pharmaceutical Care, DGHS, South Batinah Governorate
Director of Pharmaceutical Care, DGHS, North Batinah Governorate
Director of Pharmaceutical Care, DGHS, Al Dhahira Governorate
Director of Pharmaceutical Care, DGHS, North Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, South Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, Musandam Governorate
Director of Pharmaceutical Care, DGHS, Dhofar Governorate
Director of Pharmaceutical Care, DGHS, Al Wusta Governorate
Director of Pharmaceutical Care, DGHS, Buraimi Governorate
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
HOD, Pharmacy Department, Sultan Qaboos University Hospital
Pharmacist Incharge, Royal Oman Police
Pharmacist Incharge, The Diwan
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Internal Security Services
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman

After Compliments,

Kindly find attached our Circular No 16 dated 16/02/2026 Regarding Update to Health Care Professionals About Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).

Copy to:

- Director of Pharmacovigilance Department, DSC
- Director of Medicine Registration Department, DSC
- Director of Regulatory Compliance Department, DSC
- Director of Central Quality Control Lab., DSC
- Director of Medical Device Department, DSC
- Section Head of Medicine Safety Evaluation
- Section Head of Quality Problems and Medication Errors.
- Section Head of Pharmacovigilance
- Section Head of Clinical Trials



DSC
مركز سلامة الدواء
Drug Safety Center



ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩

P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489

☒ @DSCPHO Email: dscpho@moh.gov.om



نقدم بثقة
Moving Forward
with Confidence



Circular No. **16** /2026

28-08-1447 H

16-02-2026

Subject: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

The Drug Safety Center (DSC) would like to share a new safety information published by Medicine and Health products Regulatory Agency (MHRA) regarding Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION).

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) sold under brand names Ozempic and Rybelsus, which are indicated for type 2 diabetes (T2D); **and Wegovy**, which is indicated for weight management and cardiovascular risk reduction as an adjunct to a reduced-calorie diet and increased physical activity in patients with overweight or obesity.

Non-arteritic anterior ischemic optic neuropathy (NAION), a condition that can cause sudden deterioration in vision, usually in one eye at a time, has been very rarely reported in association with semaglutide in the treatment of type 2 diabetes, weight management and cardiovascular risk reduction. Patients reporting a sudden loss of vision (including partial loss) while on semaglutide treatment should be urgently referred for ophthalmological examination.

Advice for Healthcare Professionals:

- semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes mellitus and for weight management and cardiovascular risk reduction.
- semaglutide treatment may be very rarely associated with NAION, a condition which can cause vision loss, typically in one eye.
- NAION typically causes sudden, painless vision loss in one eye that is often described as a blurring or cloudiness of vision.
- privately prescribed semaglutide may not appear on the patient's medical history so if a patient presents with these symptoms, enquire about semaglutide use.
- patients reporting a sudden loss of vision (including partial loss) should be urgently referred for specialist examination by an ophthalmologist.
- discontinue semaglutide treatment if NAION is confirmed.
- advise new patients, or existing patients during medication reviews, to urgently attend eye casualty or A&E if they experience a sudden loss of vision or rapidly worsening eyesight.



نتقدم بثقة
Moving Forward
with Confidence



Advice for Healthcare Professionals to Provide to Patients:

- semaglutide treatment has, in extremely rare cases, been linked to a serious eye condition called NAION, which can affect your vision.
- NAION usually affects one eye at a time.
- if you notice a change in your eyesight, such as sudden blindness or your eyesight gets worse very quickly in one or both of your eyes during treatment with semaglutide, urgently attend eye casualty (if available in your area) or A&E.
- you may be referred for an eye examination by an ophthalmologist.

Call to report:

Semaglutide is registered in Oman, healthcare professionals, patients, and caregivers are requested to submit adverse drug reaction reports to the pharmacovigilance department in the Drug Safety Center.


Ph. Ibrahim Nasser Al Rashdi
Director General

